383 related articles for article (PubMed ID: 19851045)
1. Cisplatin ototoxicity and protection: clinical and experimental studies.
Rybak LP; Mukherjea D; Jajoo S; Ramkumar V
Tohoku J Exp Med; 2009 Nov; 219(3):177-86. PubMed ID: 19851045
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies.
Tang Q; Wang X; Jin H; Mi Y; Liu L; Dong M; Chen Y; Zou Z
Eur J Pharm Biopharm; 2021 Jun; 163():60-71. PubMed ID: 33775853
[TBL] [Abstract][Full Text] [Related]
3. Prevention and restoration of hearing loss associated with the use of cisplatin.
Chirtes F; Albu S
Biomed Res Int; 2014; 2014():925485. PubMed ID: 25140325
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin.
Lanvers-Kaminsky C; Ciarimboli G
Pharmacogenomics; 2017 Dec; 18(18):1683-1695. PubMed ID: 29173064
[TBL] [Abstract][Full Text] [Related]
5. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics of cisplatin-induced ototoxicity.
Mukherjea D; Rybak LP
Pharmacogenomics; 2011 Jul; 12(7):1039-50. PubMed ID: 21787192
[TBL] [Abstract][Full Text] [Related]
7. Future opportunities in preventing cisplatin induced ototoxicity.
van den Berg JH; Beijnen JH; Balm AJ; Schellens JH
Cancer Treat Rev; 2006 Aug; 32(5):390-7. PubMed ID: 16781082
[TBL] [Abstract][Full Text] [Related]
8. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
9. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
10. Hearing Loss After the First Low Dose Administration of Cisplatin.
Yildirim A; Fidan E; Ozdemir F
J Coll Physicians Surg Pak; 2022 Sep; 32(9):1216-1218. PubMed ID: 36089725
[TBL] [Abstract][Full Text] [Related]
11. Evaluating protective and therapeutic effects of alpha-lipoic acid on cisplatin-induced ototoxicity.
Kim KH; Lee B; Kim YR; Kim MA; Ryu N; Jung DJ; Kim UK; Baek JI; Lee KY
Cell Death Dis; 2018 Aug; 9(8):827. PubMed ID: 30068942
[TBL] [Abstract][Full Text] [Related]
12. Genetic risk factors of cisplatin induced ototoxicity in adult patients.
Talach T; Rottenberg J; Gal B; Kostrica R; Jurajda M; Kocak I; Lakomy R; Vogazianos E
Neoplasma; 2016; 63(2):263-8. PubMed ID: 26774148
[TBL] [Abstract][Full Text] [Related]
13. Aminoglycoside- and Cisplatin-Induced Ototoxicity: Mechanisms and Otoprotective Strategies.
Kros CJ; Steyger PS
Cold Spring Harb Perspect Med; 2019 Nov; 9(11):. PubMed ID: 30559254
[TBL] [Abstract][Full Text] [Related]
14. Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin.
Spracklen TF; Vorster AA; Ramma L; Dalvie S; Ramesar RS
Pharmacogenomics J; 2017 Dec; 17(6):515-520. PubMed ID: 27457817
[TBL] [Abstract][Full Text] [Related]
15. Lovastatin protects against cisplatin-induced hearing loss in mice.
Fernandez K; Spielbauer KK; Rusheen A; Wang L; Baker TG; Eyles S; Cunningham LL
Hear Res; 2020 Apr; 389():107905. PubMed ID: 32062294
[TBL] [Abstract][Full Text] [Related]
16. [Research progress on the relationship between cisplatin ototoxicity and autophagy].
Liang Z; Cheng G; Zhang T; Jia H
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Feb; 34(2):189-192. PubMed ID: 32086932
[No Abstract] [Full Text] [Related]
17. Levosimendan ameliorates cisplatin-induced ototoxicity: Rat model.
Gozeler MS; Ekinci Akdemir FN; Yildirim S; Sahin A; Eser G; Askin S
Int J Pediatr Otorhinolaryngol; 2019 Jul; 122():70-75. PubMed ID: 30978472
[TBL] [Abstract][Full Text] [Related]
18. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
Ross CJ; Katzov-Eckert H; Dubé MP; Brooks B; Rassekh SR; Barhdadi A; Feroz-Zada Y; Visscher H; Brown AM; Rieder MJ; Rogers PC; Phillips MS; Carleton BC; Hayden MR;
Nat Genet; 2009 Dec; 41(12):1345-9. PubMed ID: 19898482
[TBL] [Abstract][Full Text] [Related]
19. Economic impact of a genetic test for cisplatin-induced ototoxicity.
Dionne F; Mitton C; Rassekh R; Brooks B; Ross C; Hayden M; Carleton B
Pharmacogenomics J; 2012 Jun; 12(3):205-13. PubMed ID: 21502965
[TBL] [Abstract][Full Text] [Related]
20. Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity.
Mukherjea D; Dhukhwa A; Sapra A; Bhandari P; Woolford K; Franke J; Ramkumar V; Rybak L
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):965-982. PubMed ID: 32757852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
